bluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of “Hold” by Brokerages

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $49.14.

A number of analysts have commented on the stock. Barclays cut their price target on shares of bluebird bio from $80.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th. StockNews.com began coverage on bluebird bio in a research report on Friday. They set a “sell” rating on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $80.00 target price on shares of bluebird bio in a report on Friday, November 15th. JPMorgan Chase & Co. cut bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday, November 15th. Finally, Wells Fargo & Company reduced their price objective on shares of bluebird bio from $60.00 to $40.00 and set an “equal weight” rating for the company in a research report on Wednesday, September 25th.

bluebird bio Price Performance

bluebird bio stock opened at $8.50 on Wednesday. The stock’s 50 day moving average is $8.53 and its 200 day moving average is $13.60. bluebird bio has a one year low of $5.80 and a one year high of $38.40. The firm has a market cap of $82.64 million, a P/E ratio of -4.55 and a beta of 0.72. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Friday, September 27th. The biotechnology company reported ($8.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($8.00) by ($0.40). bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The firm had revenue of $16.10 million during the quarter, compared to analyst estimates of $16.09 million. As a group, research analysts expect that bluebird bio will post -1.35 EPS for the current year.

Institutional Trading of bluebird bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allegheny Financial Group LTD bought a new position in shares of bluebird bio in the second quarter valued at $25,000. Verition Fund Management LLC acquired a new stake in shares of bluebird bio in the 3rd quarter worth about $42,000. SG Americas Securities LLC lifted its position in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 74,185 shares in the last quarter. Captrust Financial Advisors boosted its stake in bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 77,293 shares during the last quarter. Finally, Barclays PLC boosted its stake in bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.